Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: temozolomide

Summary for Generic Name: temozolomide

Drug Master File Entries: see list14
Suppliers: see list3
Formulation / Manufacturing:see details

Pharmacology for Ingredient: temozolomide

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity

Clinical Trials for: temozolomide

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Status: Completed Condition: Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor

Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Status: Completed Condition: Recurrent Central Nervous System Neoplasm

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Status: Completed Condition: Glioblastoma; Glioma; Astrocytoma

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Status: Recruiting Condition: Neuroblastoma

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Status: Active, not recruiting Condition: Glioblastoma; Gliosarcoma

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
Status: Active, not recruiting Condition: Melanoma

ABT-888 and Temozolomide for Liver Cancer
Status: Active, not recruiting Condition: Hepatocellular Carcinoma

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma

Sarasar and Temodar for Glioblastoma Multiforme Patients
Status: Active, not recruiting Condition: Glioblastoma Multiforme; Gliosarcoma; Brain Tumors

Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients
Status: Recruiting Condition: Glioblastoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
CAPSULE;ORAL021029Aug 11, 1999RXNo5,260,291*PED<disabled>Y
Merck Sharp Dohme
CAPSULE;ORAL021029Oct 19, 2006RXNo5,260,291*PED<disabled>Y
Merck Sharp Dohme
CAPSULE;ORAL021029Aug 11, 1999RXYes5,260,291*PED<disabled>Y
CAPSULE;ORAL078879Mar 1, 2010RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology